The week's View summarizes the 10-year follow-up of the SYNTAX trial (Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery) and offers key points to remember from an article about lipid management for the prevention of atherosclerotic cardiovascular disease and a state-of-the-art review on the clinical and prognostic significance of soluble suppression of tumorigenesis-2 in heart failure.

Subscribe on iTunes | Subscribe on Google Play

Keywords: EaglesEyeView, Angioplasty, Apolipoproteins B, Atherosclerosis, Biomarkers, Blood Glucose, Carcinogenesis, Cardiomyopathy, Dilated, Cholesterol, LDL, Coronary Artery Bypass, Coronary Artery Disease, Coronary Disease, C-Reactive Protein, Defibrillators, Diabetes Mellitus, Diabetes Mellitus, Type 2, Drug-Eluting Stents, Dyslipidemias, Eicosapentaenoic Acid, Exercise, Fatty Acids, Omega-3, Fish Oils, Heart Failure, Hemodynamics, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hypercholesterolemia, Hyperlipoproteinemia Type II, Hypolipidemic Agents, Hypertriglyceridemia, Immunosuppressive Agents, Inflammation, Length of Stay, Lipids, Myocardial Infarction, Natriuretic Peptides, Paclitaxel, Percutaneous Coronary Intervention, Plaque, Atherosclerotic, Primary Prevention, Proprotein Convertases, Quality of Life, Risk Factors, Risk Management, Secondary Prevention, Sirolimus, Smoking, Stents, Stroke, Thrombosis, Triglycerides, Troponin, Troponin T, Arrhythmias, Cardiac, Metabolic Syndrome, Cardiac Surgical Procedures

< Back to Listings